C1‐INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies
Authors:
- 22 November 2012
- journal article
- research article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 24 (1) , 54-60
Abstract
Background: We analyzed the clinical response of pediatric and adolescent hereditary angioedema (HAE) patients to pdC1‐INH in the International Multicenter Prospective Angioedema C1‐INH Trials (I.M.P.A.C.T.) 1 and 2.Methods: Patients included in this post hoc analysis of prospectively collected data were between 10 and 18 yr old with type I or II HAE and a documented history of abdominal or facial attacks. Patients received a single injection of pdC1‐INH concentrate (Berinert®, CSL Behring, Marburg, Germany) 20 U/kg. Efficacy end‐points were time from the administration of study drug to onset of symptom relief and time to complete relief of all symptoms.Results: Seven pediatric patients were included in I.M.P.A.C.T.1 with only 1 attack analyzed per patient. Median time to onset of relief was 0.42 h and to complete resolution was 8.08 h. No patient experienced a worsening of symptoms during the 0–4‐h assessment period. Nine patients who experienced a total of 115 attacks were included in the analysis of I.M.P.A.C.T.2. Abdominal attacks were rated as ‘severe’ more frequently than were other types of attacks. The number of attacks per patient ranged from 2 to 42, and study participation ranged from 1 to 38 months. Median times to onset of symptom relief and to complete symptom resolution were 0.49 h and 14.1 h, respectively. Of 4 treatment‐emergent adverse events in both studies, only 2 were considered related to treatment.Conclusions: Study results showed that outcomes with pdC1‐INH treatment of HAE in pediatric patients are comparable with outcomes in adults.Keywords
This publication has 19 references indexed in Scilit:
- Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategiesEuropean Journal of Pediatrics, 2012
- C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 studyAllergy, 2011
- Hereditary Angioedema in ChildhoodPediatric Drugs, 2010
- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaAllergy, Asthma & Clinical Immunology, 2010
- Pediatric hereditary angioedema due to C1-inhibitor deficiencyAllergy, Asthma & Clinical Immunology, 2010
- Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary AngioedemaJournal of Clinical Immunology, 2010
- Pharmacokinetic analysis of human plasma–derived pasteurized C1‐inhibitor concentrate in adults and children with hereditary angioedema: a prospective studyTransfusion, 2010
- Clinical Surveillance Program Of Pediatric Hereditary Angioedema (HAE) Patients Undergoing Home TreatmentJournal of Allergy and Clinical Immunology, 2009
- Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and CourseThe American Journal of Medicine, 2006
- C1 inhibitor deficiency: consensus documentClinical and Experimental Immunology, 2005